Key result
RESILIENCE trial evaluates 11-year durability of RESILIA bioprosthetic valves in patients under 65.
Why the study?
Structural valve deterioration limits aortic bioprostheses, but recent consensus documents propose more sensitive imaging definitions to assess the long-term durability of novel RESILIA tissue in patients under 65 years old.
Does RESILIA tissue bioprosthetic AVR demonstrate long-term clinical and imaging durability in patients <65 years of age?
Does RESILIA tissue bioprosthetic AVR demonstrate long-term clinical and imaging durability in patients <65 years of age?
Answers are grounded in this paper and cite their sources.
The RESILIENCE trial is designed to prospectively evaluate the long-term clinical and imaging durability of RESILIA tissue bioprosthetic aortic valves in patients under 65 years old over 11 years.
Background: Structural valve deterioration (SVD) is the Achilles heel of bioprosthetic valves used for aortic valve replacement (AVR). SVD has been traditionally defined based upon the requirement for valve reintervention. Recent expert consensus documents have proposed more granular and sensitive definitions of SVD based on the occurrence of morphological and hemodynamic valve deterioration measured by transthoracic echocardiography (TTE) and computed tomography (CT). RESILIA™ tissue is a new tissue technology incorporating a stable-capping process which permanently blocks residual aldehyde groups known to bind with calcium.Methods: Two clinical trials of RESILIA tissue valves have shown promising safety and effectiveness outcomes through early follow up. We here describe the design of the RESILIENCE trial (ClinicalTrials.gov: NCT03680040), which evaluates the long-term durability of RESILIA tissue bioprosthetic AVR in patients <65 years of age. Up to 250 patients implanted with a RESILIA tissue valve will prospectively undergo a TTE and non-contrast CT at 5, 7, 9, and 11 years; the echos and CTs will be analyzed by core laboratories.Results: The primary outcome is the occurrence of valve re-intervention or death related to structural valve failure. The secondary outcomes are the volume of valve leaflet calcification measured by CT and the occurrence of Stage 2 (moderate) or 3 (severe) hemodynamic SVD measured by TTE.Conclusion: The RESILIENCE trial is the first prospective study to associate both clinical and imaging definitions of SVD with long-term (11 years) bioprosthetic valve durability.
No takes yet. Share an insight, caveat, or question.
Pîbarot et al. (2019) studied Aortic valve replacement (n=250). RESILIA tissue bioprosthetic valve was evaluated on Occurrence of valve re-intervention or death related to structural valve failure. The RESILIENCE trial is a prospective, single-arm study designed to evaluate the 11-year durability of RESILIA tissue bioprosthetic valves in up to 250 patients <65 years of age.
Synapse has enriched 10 related papers. Consider them for comparative context: